Checkpoint inhibitors plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Background: We conducted a meta-analysis to evaluate the efficacy and safety of upfront add-on immunotherapy for advanced non-small cell lung cancers (NSCLC). Methods: We performed a literature search on first-line chemotherapy ± immunotherapy in NSCLC. We utilized Revman version 5.3 to calculate th...

Full description

Bibliographic Details

Published in:	Future Science OA
Main Authors:	Aung Myint Tun, Kyaw Zin Thein, Wai Lin Thein, Elizabeth Guevara
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2019-10-01
Subjects:	advanced non-small-cell lung cancer checkpoint inhibitors chemotherapy first-line therapy immune-related adverse events objective response rate
Online Access:	https://www.future-science.com/doi/10.2144/fsoa-2019-0081